Asset Planning Inc Invests $33,000 in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Asset Planning Inc acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 100 shares of the medical research company’s stock, valued at approximately $33,000.

A number of other large investors have also modified their holdings of BIO. Gladius Capital Management LP acquired a new position in shares of Bio-Rad Laboratories during the third quarter worth $32,000. UMB Bank n.a. grew its stake in shares of Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after purchasing an additional 32 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in shares of Bio-Rad Laboratories during the third quarter worth $55,000. Quarry LP grew its stake in shares of Bio-Rad Laboratories by 38.1% during the third quarter. Quarry LP now owns 297 shares of the medical research company’s stock worth $99,000 after purchasing an additional 82 shares in the last quarter. Finally, Assetmark Inc. grew its stake in shares of Bio-Rad Laboratories by 84.8% during the third quarter. Assetmark Inc. now owns 305 shares of the medical research company’s stock worth $102,000 after purchasing an additional 140 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Analyst Upgrades and Downgrades

BIO has been the subject of a number of analyst reports. StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Citigroup boosted their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, Wells Fargo & Company decreased their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Bio-Rad Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $395.20.

Bio-Rad Laboratories Stock Performance

NYSE BIO opened at $276.55 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. Bio-Rad Laboratories, Inc. has a 1 year low of $262.12 and a 1 year high of $387.99. The company has a market capitalization of $7.74 billion, a PE ratio of -10.12 and a beta of 0.90. The company has a fifty day moving average of $338.72 and a two-hundred day moving average of $336.18.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. As a group, analysts expect that Bio-Rad Laboratories, Inc. will post 10.33 earnings per share for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.